ThromboGenics Jetrea wins approval for vitreomacular traction treatment in Europe
Jetrea, which is administered through a one-time, single intravitreal injection, breaks down the protein fibers which cause the abnormal traction between vitreous and macula that causes VMT. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.